Clinical trial
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
NCT00493454 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00493454 |
|---|---|
| Title | Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas |
| Official title | Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Biogen Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Zevalin, Rituximab, ^111 In Ibritumomab Tiuxetan |
| Enrollment | 6 |
| Start date | Apr 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Jun 28, 2007 |
| Last update posted | May 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: